BRAF and thyroid cancer: Molecular markers have emerged as a promising approach in cases of indeterminate thyroid FNA specimens, offering crucial insights to guide decisions regarding primary surgical treatment.[5,41] The prevalence of BRAF V600E mutation differs in different subtype of thyroid cancer, depending on the detection method and size of study cohort.